Search Results - "Bylow, Kathryn"

Double‐blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma by Grivas, Petros D., Daignault, Stephanie, Tagawa, Scott T., Nanus, David M., Stadler, Walter M., Dreicer, Robert, Kohli, Manish, Petrylak, Daniel P., Vaughn, David J., Bylow, Kathryn A., Wong, Steven G., Sottnik, Joseph L., Keller, Evan T., Al‐Hawary, Mahmoud, Smith, David C., Hussain, Maha

“…BACKGROUND Angiogenesis contributes to the progression of urothelial carcinoma (UC). In the current study, the authors investigated the role of maintenance…”
Get full text

Successful Targeting of Somatic VHL Alterations With Belzutifan in Two Cases by Thapa, Bicky, Shreenivas, Aditya, Bylow, Kathryn, Chen, Hui-Zi, George, Ben, Kurzrock, Razelle

“…Clear cell renal cell carcinoma (RCC) is commonly associated with alterations in the VHL tumor suppressor gene, resulting in upregulation of hypoxia-inducible…”
Get full text

Long-Term Outcomes of Dose-Escalated Pelvic Lymph Node Intensity-Modulated Radiation Therapy (IMRT) With a Simultaneous Hypofractionated Boost to the Prostate for Very High-Risk Adenocarcinoma of the Prostate: A Prospective Phase II Clinical Trial by Hall, William A., Bedi, Meena, Kilari, Deepak, Bylow, Kathryn A., Burfeind, John, Johnstone, Candice, Siker, Malika, Currey, Adam, See, William A., Nelson, Ariel, Johnson, Scott, Straza, Michael, Lawton, Colleen A.F.

“…There remains limited data as to the feasibility, safety, and efficacy of higher doses of elective radiation therapy to the pelvic lymph nodes in men with…”
Get full text

Patient Anxiety About Prostate Cancer Independently Predicts Early Initiation of Androgen Deprivation Therapy for Biochemical Cancer Recurrence in Older Men: A Prospective Cohort Study by DALE, William, HEMMERICH, Joshua, BYLOW, Kathryn, MOHILE, Supriya, MULLANEY, Mary, STADLER, Walter M

“…Androgen deprivation therapy (ADT) is first-line therapy for patients with prostate cancer (PCA) who experience biochemical recurrence (BCR). However, the…”
Get full text

The relationship between anxiety about prostate cancer among patients with biochemical cancer recurrence and the use of complementary and alternative medicines, diet, and exercise by Lee, Richard T, Hemmerich, Joshua A, Kwon, Nancy, Bylow, Kathryn, Stadler, Walter M, Mohile, Supriya G, Dale, William

“…ObjectiveWe aimed to explore associations between anxiety and specific health behaviors such as complementary and alternative medicine (CAM), diet, and…”
Get full text

TEMPORAL ARTERITIS: THE IMPORTANCE OF RECOGNIZING SENESCENT CHANGES VERSUS QUIESCENT DISEASE IN A TEMPORAL ARTERY BIOPSY by Bylow, Kathryn A., Brauner, Daniel J.

Get full text

Phase II Trial of Carboplatin and Paclitaxel in Papillary Renal Cell Carcinoma by Bylow, Kathryn A, Atkins, Michael B, Posadas, Edwin M, Stadler, Walter M, McDermott, David F

“…Abstract Background Cytotoxic chemotherapy has not been well investigated in non–clear-cell renal cell carcinoma (RCC). A phase II study was thus conducted to…”
Get full text

Men Moving Forward: Incorporating Sexual Health Of Prostate Cancer Survivors In Exercise Trials: 1894 by Born, Kathryn A., Stolley, Melinda, Flynn, Kathryn, Sheean, Patricia, Kilari, Deepak, Bylow, Kathryn, Papanek, Paula

Get full text

Disparities in medical oncology visit adherence among African American (AA) men with prostate cancer (pCa) by Nelson, Ariel Ann, Ladwig, Christina, Riemersma, Kristin, Bylow, Kathryn A., Kilari, Deepak

“…e18671 Background: AA patients (pts) with pCa tend to have worse outcomes when compared to Caucasians. Disparities in access to healthcare among AA pts with…”
Get full text

Impact of pre-treatment hemoglobin (Hgb) on outcomes in metastatic castration resistant prostate cancer (mCRPC) with lutetium-177-PSMA-617 (Lu-177) by Nelson, Ariel Ann, Riemersma, Kristin, Bylow, Kathryn A., Holt, Michael, Kilari, Deepak

“…e17065 Background: The Phase 3 VISION and TheraP trials excluded men with Hgb≤ 9 g/dL or blood transfusion within 30 days of Lu-177. Patients (pts) with mCRPC…”
Get full text

Immunohistochemical (IHC) subtypes of metastatic bladder cancer (mBC) using GATA3 and CK5/6 by Nelson, Ariel Ann, Molina Nunez, Mariel, Bylow, Kathryn A., Szabo, Aniko, Iczkowski, Kenneth, Kilari, Deepak

“…557 Background: Genomic analyses have identified that bladder cancers can be divided into distinct molecular subtypes: luminal and basal. IHC markers GATA3 and…”
Get full text

Impact of pre-existing anemia and/or packed red blood cell transfusion prior to Radium-223 administration on oncologic outcomes by Pierro, Michael, Nelson, Ariel Ann, Xie, John, Jang, Albert, Bylow, Kathryn A., Barata, Pedro C., Lawton, Colleen Anne, Kilari, Deepak

“…67 Background: Radium-223 (Ra-223), a targeted alpha-emitting radiopharmaceutical approved for the treatment of metastatic prostate cancer (mPC), can cause…”
Get full text

Predictors of response to platinum (Pt)-based chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) by Kilari, Deepak, Bylow, Kathryn A., Berlin, Kathryn E. K.

“…Abstract only e575 Background: Aggressive variant PC (AVPC) is a well-described subtype of PC which portends a poor prognosis. Studies have shown an increase…”
Get full text

Abstract B006: Developing Men Moving Forward, a lifestyle intervention for African American prostate cancer survivors by Jarrett, Jamal A., Matthews, Lauren, Sheean, Patricia, Flynn, Kathryn, Bylow, Kathryn, Kilari, Deepak, Papanek, Paula, Johnson, Tina, Stolley, Melinda

“…African American men are disproportionally affected by high prostate cancer incidence and mortality, and also comorbidities. African American prostate cancer…”
Get full text

A single-arm, open-label, phase 2 study evaluating pacritinib for patients with biochemical recurrence after definitive treatment for prostate cancer: Blast study by Kilari, Deepak, Szabo, Aniko, Hall, William A., Nelson, Ariel Ann, Johnson, Scott, Giever, Thomas A., Burfeind, John, Tolat, Parag, Bylow, Kathryn A., Iczkowski, Kenneth, Sun, Yunguang, Rui, Hallgeir, Thomas, James P., Nevalainen, Marja

“…Abstract only TPS220 Background: Androgen deprivation therapy (ADT) achieved with gonadotropin releasing hormone (GnRH) agonist or antagonist is considered the…”
Get full text

The Role of Metastasectomy in Urothelial Carcinoma: Where Are We in 2020? by Lemke, Emily, Sahasrabudhe, Deepak, Guancial, Elizabeth, Bylow, Kathryn, Johnson, Scott, Messing, Edward, Kilari, Deepak

“…Systemic therapy is the mainstay of treatment for metastatic urothelial carcinoma (UC). Responses to first-line platinum-based therapy tend to be short-lived…”
Get full text

An Annual Symposium on Disparities in Milwaukee, WI, with a 2023 Focus on Older Adults with Cancer by Kamaraju, Sailaja, McKoy, June, Williams, Grant R., Gilmore, Nikesha, Minami, Christina, Bylow, Kathryn, Rajalingam, Helena, Cortina, Chandler S., Beckert, Angela, Stolley, Melinda, Bullock, Dan, Kurzrock, Razelle, Jatoi, Aminah

“…Purpose of Review Cancer-related inequities are prevalent in Wisconsin, with lower survival rates for breast, colorectal, and lung cancer patients from…”
Get full text

A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study by Kilari, Deepak, Szabo, Aniko, Bylow, Kathryn A., Alter, Robert S., Nelson, Ariel Ann, Lemke, Emily, Hall, William Adrian, Johnson, Scott, Langenstroer, Peter, Jacobsohn, Kenneth, Davis, Nancy B., Fung, Chunkit, Milowsky, Matthew I.

“…Abstract only TPS4591 Background: ABACUS and PURE-01 trials demonstrated the activity of single agent atezolizumab and pembrolizumab respectively as…”
Get full text

Abstract A088: Examining associations between objective and perceived stress and allostatic load in African American prostate cancer survivors by Awoyinka, Iwalola, Kilari, Deepak, Bylow, Kathryn, Knight, Jennifer, Visotcky, Alexis, Banerjee, Anjishnu, Sheean, Patricia, Papanek, Paula, Stolley, Melinda

“…Background. Racial disparities in prostate cancer survivorship persist despite clinical advancements. Stress has been implicated as a potential driver of these…”
Get full text

Falls and Physical Performance Deficits in Older Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy by Bylow, Kathryn, Dale, William, Mustian, Karen, Stadler, Walter M, Rodin, Miriam, Hall, William, Lachs, Mark, Mohile, Supriya G

“…Objectives Men experience a decrease in lean muscle mass and strength during the first year of androgen deprivation therapy (ADT). The prevalence of falls and…”
Get full text